#75 Strong Clinical Relevance
High-quality evidence with meaningful patient or clinical significance.
Clinicians need evidence-based dosing guidance for cannabis products, and this Phase I trial addresses a critical gap by systematically mapping how oral THC doses affect anxiety outcomes. Understanding dose-response relationships allows providers to individualize THC prescribing more safely and effectively rather than relying on patient trial-and-error. Results from this trial could inform clinical protocols and help patients achieve therapeutic benefits at lower doses with reduced side effects.
Avicanna is sponsoring a Phase I trial at the University of Calgary to establish dose-response relationships for oral THC capsules in anxiety management, addressing a significant gap in evidence-based dosing guidance for cannabinoid therapeutics. This research is clinically important because oral THC formulations lack standardized dosing protocols and robust pharmacokinetic data in controlled settings, leaving practitioners to rely largely on patient-reported outcomes and anecdotal guidance. The trial will generate systematic data on how different THC doses affect anxiety symptoms, which can inform more precise, individualized prescribing practices and help clinicians anticipate therapeutic windows and adverse effects. Phase I safety and tolerability data from this study may also establish a foundation for larger Phase II/III trials that could eventually support regulatory approval and insurance coverage. For clinicians treating anxiety with cannabis-derived products, results from this trial could provide evidence-based dosing recommendations that improve efficacy while minimizing patient side effects and overdose risk. Physicians should monitor this trial’s progress as standardized, manufacturer-backed dosing data becomes increasingly essential for safe and effective cannabis prescribing.
“What we’re seeing with rigorous dose-response trials like this one is finally the data we need to move beyond anecdotal dosing, because the truth is most patients are either under-dosed and getting no benefit or over-dosed and experiencing side effects that turn them away from cannabis medicine altogether.”
🧠 While industry-sponsored trials offer valuable opportunities to establish dose-response relationships for cannabis products, clinicians should recognize that such research exists within a complex landscape of commercial interests, regulatory constraints, and limited long-term safety data. This particular Phase I trial examining oral THC dosing for anxiety addresses a genuine clinical gap, as most cannabis research has focused on smoked products rather than standardized oral formulations, and anxiety remains one of the most common patient-reported reasons for use. However, the anxiolytic effects of THC are notoriously variable and dose-dependent, with some patients experiencing paradoxical increases in anxiety at higher doses, making it critical that any emerging dosing guidance account for individual differences in metabolism, prior cannabis exposure, and comorbid conditions. In practice, clinicians should await peer-reviewed publication of such trials before incorporating specific dosing recommendations into their care, while continuing to discuss with patients the current uncertainty around optimal THC dos
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it: